Changeflow GovPing Healthcare & Life Sciences Particle-Based Separation of Extracellular Vesi...
Routine Notice Added Final

Particle-Based Separation of Extracellular Vesicles, University of Idaho, Apr 23, 2026

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The University of Idaho has published patent application US20260109943A1, covering methods, compositions, and kits for isolating extracellular vesicles (EVs) using a chitin-based stationary phase material functionalized with a fusion protein comprising a lactadherin C1C2 domain, a chitin-binding domain (CBD), and an intein. The application, filed October 17, 2025, was published April 23, 2026. CPC classifications include C12N 5/04, C07K 14/46, and C07K 2319/00. Inventors are listed as Ching-An Peng.

“These methods and systems achieve EV isolation more efficiently, at lower cost, and with higher purity and quality of the isolated EVs, as compared to prior technologies.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.

What changed

The University of Idaho published a patent application for EV isolation methods that use chitin-based stationary phase materials functionalized with a fusion protein combining a lactadherin C1C2 domain, a chitin-binding domain, and an intein. The application was filed October 17, 2025, and published April 23, 2026.

Parties interested in EV-based diagnostics, therapeutics, or research tools should monitor the prosecution of this application, which could affect freedom-to-operate assessments for competing EV isolation technologies once the patent grants. Researchers and manufacturers developing EV isolation kits or workflows may wish to review the claim scope during the examination period.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PARTICLE-BASED SEPARATION OF EXTRACELLULAR VESICLES

Application US20260109943A1 Kind: A1 Apr 23, 2026

Assignee

University of Idaho

Inventors

Ching-An Peng

Abstract

Provided herein are methods, compositions, and kits for isolating extracellular vesicles (EVs). These methods and systems achieve EV isolation more efficiently, at lower cost, and with higher purity and quality of the isolated EVs, as compared to prior technologies. The disclosed methods include contacting a sample with a chitin-based stationary phase material functionalized with a fusion protein, wherein the fusion protein comprises i) a lactadherin C1C2 domain, ii) a chitin-binding domain (CBD), and iii) an intein positioned between the lactadherin C1C2 domain and the CBD.

CPC Classifications

C12N 5/04 C07K 14/46 C07K 2319/00

Filing Date

2025-10-17

Application No.

19362156

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biotechnology research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!